Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Verapamil in Longstanding Type 1 Diabetes
NCT05847413Phase 1Completed
- Sponsor
- Benaroya Research Institute
- Start
- May 2020
- Primary completion
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of verapamil in type 1 diabetes mellitus (T1D), sponsored by Benaroya Research Institute. Primary endpoint: Proportion of individuals with peak MMTT stimulated C-peptide > 0.017 pmol/mL at 12 weeks. Started May 2020; status: completed.
02
Drugs
verapamil
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT05847413.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05847413.